ClinicalTrials.gg
CompletedNCT04214691Updated Apr 27, 2025

A Study of Newly Formulated Tylenol Tablet (Acetaminophen) and Tylenol 8 Hour (H) Extended Release (ER) Tablet (Acetaminophen) in Healthy Participants

A Phase 1 interventional study of Acetaminophen in Healthy, sponsored by Janssen Korea, Ltd., Korea. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Janssen Korea, Ltd., Korea (part of Johnson & Johnson) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the bioequivalence of the newly formulated Tylenol tablet (acetaminophen 650 milligram [mg]) with respect to the Tylenol 8 hour (H) extended-release (ER) tablet (acetaminophen 650 mg) in healthy participants under fed conditions.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Korea, Ltd., Korea is the lead sponsor of 79 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy on the basis of physical examination, medical history, vital signs, and 12-lead (ECG) performed at screening. If there are abnormalities, they must be consistent with the underlying illness in the study population. This determination must be recorded in the participant's source documents
  • Healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel including liver enzymes, other specific tests, hematology, urinalysis or breathing alcohol test are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not . This determination must be recorded in the participant's source documents and initialed by the investigator
  • Blood pressure (after the participant is sitting for 5 minutes) between 90 and 140 millimeters of Mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic
  • Have no history of psychiatric disorder within the 5 years prior to the screening
  • Have no history of gastrointestinal resection that may affect drug absorption

Exclusion criteria

Exclusion Criteria:

  • abnormal physical examination, vital signs, or 12 lead at screening as deemed appropriate by the investigator
  • Known allergies, , or intolerance to acetaminophen or its
  • History of within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence)
  • Taken any disallowed therapies as noted in local prescribing information, concomitant therapy before the planned first dose of study drug
  • Use of any prescription or nonprescription medication (including oriental medicines) within 30 days before the first dose of the study drug is scheduled
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1: Reference Drug + Test Drug (RT)

    Participants will receive 8 hour (H) extended-release (ER) acetaminophen tablet orally in period 1 (Reference) followed by newly formulated acetaminophen tablet orally in period 2 (Test). Each period will be separated by a washout period of at least 7 days.

    Drug: Acetaminophen

  • Experimental
    Treatment Sequence 2: Test Drug + Reference Drug (TR)

    Participants will receive newly formulated acetaminophen tablet orally in period 1 (Test) followed by 8H ER acetaminophen tablet orally in period 2 (Reference). Each period will be separated by a washout period of at least 7 days.

    Drug: Acetaminophen

Interventions

  • Acetaminophen tablet will be administered orally in treatment sequence 1 and 2.

    Also known as: Tylenol

06

What researchers measure

Primary outcomes

  1. Maximum Observed Analyte Concentration (Cmax)

    Cmax is the maximum observed analyte concentration.

    Time frame: Up to 24 hours post-dose

  2. Area Under the Concentration-time Curve From Time 0 to Time of the Last Measurable Concentration (AUC [0-last])

    AUC (0-last) is the area under the concentration-time curve from time 0 to time of the last measurable concentration (non-below quantitation limit).

    Time frame: Up to 24 hours post-dose

Secondary outcomes

  1. Area Under the Concentration-time Curve From Time 0 to Infinite Time (AUC[0-infinity])

    AUC(0-infinity) is the area under the plasma concentration-time curve from time 0 to infinite time, calculated as the sum of AUC (0-last) and C(last)/lambda(z).

    Time frame: Up to 24 hours post-dose

  2. Percentage of Area Under the Concentration-time Curve Extrapolated from Last Measurable Concentration to Infinite Time (extrapolated %AUCinfinity)

    Percentage of area under the concentration-time curve extrapolated from last measurable concentration to infinite time (extrapolated %AUCinfinity) is calculated using formula: (AUC \[0-infinity\] minus (-) AUC \[0-last\]/AUC \[0-infinity\])\*100.

    Time frame: Up to 24 hours post-dose

  3. Time to Reach the Maximum Observed Analyte Concentration (Tmax)

    Tmax is the time to reach the maximum observed analyte plasma concentration.

    Time frame: Up to 24 hours post-dose

  4. Time to Last Measurable Plasma Concentration (T [last])

    Tlast is the time to last measurable plasma concentration.

    Time frame: Up to 24 hours post-dose

  5. Elimination Rate Constant (Lambda [z])

    Lambda (z) is the apparent terminal elimination rate constant determined by linear regression using the terminal log-linear phase of the log transformed concentration-time curve.

    Time frame: Up to 24 hours post-dose

  6. Elimination Half-Life (t 1/2)

    t1/2 is defined as apparent is associated terminal elimination half-life associated with the terminal slope (lambda \[z\]) of the semilogarithmic drug concentration-time curve, calculated as: 0.693/lambda(z).

    Time frame: Up to 24 hours post-dose

  7. Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

    Time frame: Up to 41 days

07

Study locations

1 site
  • H plus Yangji Hospital
    Seoul, 8779, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Jan 2020, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2019
First posted
Jan 2, 2020
StartActual
Dec 17, 2019
Primary completionActual
Jan 16, 2020
CompletionActual
Feb 7, 2020
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04214691
Responsible party
Sponsor
First posted
Jan 2, 2020
Start date
Dec 17, 2019
Primary completion
Jan 16, 2020
Completion
Feb 7, 2020
Last update
Apr 27, 2025

Study contacts

Janssen Korea, Ltd., Korea Clinical Trial
study director · Janssen Korea, Ltd., Korea

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion